Health ❯ Healthcare ❯ Neurology

Cognitive Disorders

Alzheimer's Disease Dementia Mild Cognitive Impairment Alzheimer's Disease Treatments Parkinson's Disease Mild Dementia Dementia Treatments Dementia Risk Factors Early Diagnosis Dementia Management

p‑Tau217 Blood Tests Boost Alzheimer’s Diagnosis and Predict Onset Within a Few Years

For now, investigators advise research use focused on trial enrichment rather than routine screening or individual prognoses.

Exeter-Led Review Flags Shingles Vaccine, Riluzole and Viagra for Alzheimer’s Trials

Long COVID Linked to Enlarged, Underperfused Choroid Plexus and Alzheimer’s Biomarkers

Brazil Authorizes Leqembi for Early-Stage Alzheimer’s Treatment

IQWiG Says Leqembi Shows No Added Benefit for Early Alzheimer’s Patients

Fuji Rebio Seeks Japan Approval for Blood Test to Aid Alzheimer’s Diagnosis

Mayo Clinic Model Estimates 10-Year and Lifetime Risk of Cognitive Decline

Health Canada Conditionally Authorizes First Alzheimer’s Drug to Slow Early Decline

BioCog Tablet Test Sharpens Primary Care Detection of Cognitive Impairment Linked to Alzheimer’s

MRI Measure of Brain Iron Predicts Future Cognitive Decline, Radiology Study Finds

UK Launches NHS Trial of £100 Blood Test to Speed Alzheimer’s Diagnosis

FDA Clears At-Home Leqembi Injection for Weekly Maintenance in Early Alzheimer’s

Experts Warn Older Adults: Irregular Sleep Raises Cardiovascular and Cognitive Risks

EMA Recommends Donanemab for Early Alzheimer’s in the EU

Frequent Gabapentin Prescriptions Tied to Increased Dementia and Cognitive Impairment Risk

Parkinson’s Onset Side Predicts Divergent Cognitive and Mental Health Trajectories

FDA Approves 95% Sensitive Blood Test for Alzheimer’s

FDA Approves First Blood Test for Alzheimer’s Diagnosis

FDA Approves First Blood Test for Early Alzheimer’s Diagnosis in Symptomatic Adults

FDA Approves First Blood Test for Alzheimer’s Diagnosis